PL3456333T3 - Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego - Google Patents

Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego

Info

Publication number: PL3456333T3
Authority: PL; Poland
Prior art keywords: imetelstat; treatment; telomerase inhibitor; myelodisplastic syndrome; myelodisplastic
Prior art date: 2012-12-07

Application number

PL18196690T

Other languages

English (en)

Inventor

Monic J. Stuart

Stephen Kelsey

Original Assignee

Geron Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-07

Filing date

2013-11-15

Publication date

2020-09-21

2013-03-15 Priority claimed from US13/841,711 external-priority patent/US9375485B2/en

2013-11-15 Application filed by Geron Corporation filed Critical Geron Corporation

2020-09-21 Publication of PL3456333T3 publication Critical patent/PL3456333T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Diabetes (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL18196690T 2012-12-07 2013-11-15 Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego PL3456333T3 (pl)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201261734941P	2012-12-07	2012-12-07
US201361799069P	2013-03-15	2013-03-15
US13/841,711 US9375485B2 (en)	2012-12-07	2013-03-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P	2013-11-05	2013-11-05
EP13861008.4A EP2928477B1 (en)	2012-12-07	2013-11-15	Use of the telomerase inhibitor imetelstat for the treatment of myelofibrosis
PCT/US2013/070437 WO2014088785A1 (en)	2012-12-07	2013-11-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP18196690.4A EP3456333B8 (en)	2012-12-07	2013-11-15	Use of the telomerase inhibitor imetelstat for the treatment of myelodysplastic syndrome

Publications (1)

Publication Number	Publication Date
PL3456333T3 true PL3456333T3 (pl)	2020-09-21

Family

ID=50883867

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL13861008T PL2928477T3 (pl)	2012-12-07	2013-11-15	Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy
PL19187756.2T PL3646876T3 (pl)	2012-12-07	2013-11-15	Inhibitor telomerazy, imetelstat do leczenia zaburzeń mieloproliferacyjnych i nowotworów mieloproliferacyjnych
PL18196690T PL3456333T3 (pl)	2012-12-07	2013-11-15	Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL13861008T PL2928477T3 (pl)	2012-12-07	2013-11-15	Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy
PL19187756.2T PL3646876T3 (pl)	2012-12-07	2013-11-15	Inhibitor telomerazy, imetelstat do leczenia zaburzeń mieloproliferacyjnych i nowotworów mieloproliferacyjnych

Country Status (37)

Country	Link
EP (3)	EP3456333B8 (pl)
JP (6)	JP6433911B2 (pl)
KR (4)	KR102294819B1 (pl)
CN (2)	CN111617252A (pl)
AP (1)	AP2015008504A0 (pl)
AU (4)	AU2013356533B2 (pl)
BR (1)	BR112015013260A2 (pl)
CA (2)	CA3188494A1 (pl)
CL (2)	CL2015001530A1 (pl)
CY (2)	CY1122169T1 (pl)
DK (3)	DK3646876T3 (pl)
EA (1)	EA032973B1 (pl)
ES (3)	ES2982897T3 (pl)
FI (2)	FI3646876T3 (pl)
FR (1)	FR25C1016I1 (pl)
HK (1)	HK1210940A1 (pl)
HR (3)	HRP20240624T1 (pl)
HU (4)	HUE066402T2 (pl)
IL (3)	IL280144B2 (pl)
LT (4)	LT3646876T (pl)
MA (2)	MA45504B1 (pl)
ME (1)	ME03538B (pl)
MX (3)	MX372753B (pl)
MY (2)	MY180634A (pl)
NL (1)	NL301326I2 (pl)
NZ (1)	NZ708920A (pl)
PH (2)	PH12019501008A1 (pl)
PL (3)	PL2928477T3 (pl)
PT (3)	PT3456333T (pl)
RS (2)	RS59363B1 (pl)
SG (3)	SG11201504383TA (pl)
SI (3)	SI3456333T1 (pl)
SM (2)	SMT201900567T1 (pl)
TN (1)	TN2015000249A1 (pl)
UA (3)	UA128370C2 (pl)
WO (1)	WO2014088785A1 (pl)
ZA (3)	ZA201504124B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS56361B1 (sr)	2004-07-02	2017-12-29	Geron Corp	Sinteza zaštićenih 3'-amino nukleozidnih monomera
US9375485B2 (en)	2012-12-07	2016-06-28	Geron Corporation	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
WO2015021153A1 (en)	2013-08-07	2015-02-12	Incyte Corporation	Sustained release dosage forms for a jak1 inhibitor
ES2717777T3 (es) *	2013-11-06	2019-06-25	Mayo Found Medical Education & Res	Métodos y materiales para tratar neoplasias hematológicas
MA42569B1 (fr)	2015-04-23	2020-08-31	Geron Corp	Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
EP3318276A1 (en) *	2016-11-04	2018-05-09	Janssen Biotech, Inc.	Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
TWI879717B (zh)	2017-07-28	2025-04-11	美商傑龍公司	治療骨髓增生不良症候群之方法
IL319432A (en)	2018-04-30	2025-05-01	Kartos Therapeutics Inc	Methods of treating cancer
KR20210043499A (ko)	2018-05-25	2021-04-21	카토스 테라퓨틱스, 인크.	골수증식성 신생물 치료 방법
EP3829651A4 (en) *	2018-07-31	2022-05-04	Geron Corporation	METHODS OF IDENTIFYING PATIENTS WHO WILL BENEFIT FROM TREATMENT WITH A TELOMERASE INHIBITOR
SG11202105573PA (en)	2018-11-29	2021-06-29	Geron Corp	Methods of treating myelodysplastic syndrome
EP4054594A4 (en) *	2019-11-04	2023-12-13	Geron Corporation	USE OF A JANUS KINASE INHIBITOR AND A TELOMERASE INHIBITOR FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
JP2021157248A (ja) *	2020-03-25	2021-10-07	パイオニア株式会社	状況出力装置
CN115776909A (zh) *	2020-07-17	2023-03-10	美国杰龙生物医药公司	皮下端粒酶抑制剂组合物及其使用方法
WO2022159760A1 (en) *	2021-01-22	2022-07-28	The Regents Of The University Of California	Methods for treating and ameliorating cancer
WO2024259369A1 (en) *	2023-06-14	2024-12-19	Rarecells Inc.	Compositions targeting giant cells in blood disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5489508A (en)	1992-05-13	1996-02-06	University Of Texas System Board Of Regents	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en)	1994-07-07	1996-12-10	Geron Corporation	Mammalian telomerase
US5958680A (en)	1994-07-07	1999-09-28	Geron Corporation	Mammalian telomerase
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5770613A (en)	1995-09-29	1998-06-23	Geron Corporation	Telomerase inhibitors
US5767278A (en)	1995-10-06	1998-06-16	Geron Corporation	Telomerase inhibitors
US6261836B1 (en)	1996-10-01	2001-07-17	Geron Corporation	Telomerase
US6444650B1 (en)	1996-10-01	2002-09-03	Geron Corporation	Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
AU733610B2 (en)	1996-12-20	2001-05-17	Geron Corporation	Methods for detecting and inhibiting the RNA component of telomerase
US6331399B1 (en)	2000-05-16	2001-12-18	Isis Pharmaceuticals, Inc.	Antisense inhibition of tert expression
AU2004209428A1 (en) *	2003-01-31	2004-08-19	Jessie L.-S. Au	Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) *	2003-07-11	2006-03-08	暨南大学	抑制白血病细胞端粒酶活性的反义核酸及其应用
JP4690324B2 (ja)	2003-09-09	2011-06-01	ジェロン・コーポレーション	テロメラーゼ阻害のための改変オリゴヌクレオチド
US20050282893A1 (en) *	2004-01-30	2005-12-22	Au Jessie L	Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
RS56361B1 (sr)	2004-07-02	2017-12-29	Geron Corp	Sinteza zaštićenih 3'-amino nukleozidnih monomera
FR2877013A1 (fr)	2004-10-27	2006-04-28	Assist Publ Hopitaux De Paris	Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en)	2005-01-21	2006-07-27	Bahou Wadie F	Methods of diagnosing essential thrombocythemia
WO2006113426A2 (en) *	2005-04-15	2006-10-26	Geron Corporation	Cancer treatment by combined inhibition of telomerase and tubulin activities
WO2006113470A2 (en)	2005-04-15	2006-10-26	Geron Corporation	Cancer treatment by combined inhibition of proteasome and telomerase activities
US20070224598A1 (en)	2006-03-15	2007-09-27	The Methodist Hospital Research Institute	System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en)	2006-07-21	2008-01-24	Cephalon, Inc.	JAK inhibitors for treatment of myeloproliferative disorders
PL2101789T3 (pl)	2006-10-30	2015-05-29	Geron Corp	Inhibitor telomerazy skojarzony z gemcytabiną do leczenia nowotworu
CN101220044B (zh) *	2008-01-21	2010-06-02	中国药科大学	端粒酶抑制剂及其制备方法和用途

2013
- 2013-11-15 RS RSP20191271 patent/RS59363B1/sr unknown
- 2013-11-15 PT PT181966904T patent/PT3456333T/pt unknown
- 2013-11-15 HK HK15111700.1A patent/HK1210940A1/xx unknown
- 2013-11-15 SM SM20190567T patent/SMT201900567T1/it unknown
- 2013-11-15 EP EP18196690.4A patent/EP3456333B8/en active Active
- 2013-11-15 SG SG11201504383TA patent/SG11201504383TA/en unknown
- 2013-11-15 SM SM20200328T patent/SMT202000328T1/it unknown
- 2013-11-15 DK DK19187756.2T patent/DK3646876T3/da active
- 2013-11-15 AU AU2013356533A patent/AU2013356533B2/en active Active
- 2013-11-15 NZ NZ708920A patent/NZ708920A/en unknown
- 2013-11-15 KR KR1020157017240A patent/KR102294819B1/ko active Active
- 2013-11-15 UA UAA202100419A patent/UA128370C2/uk unknown
- 2013-11-15 PT PT191877562T patent/PT3646876T/pt unknown
- 2013-11-15 MA MA45504A patent/MA45504B1/fr unknown
- 2013-11-15 DK DK13861008.4T patent/DK2928477T3/da active
- 2013-11-15 LT LTEP19187756.2T patent/LT3646876T/lt unknown
- 2013-11-15 ES ES19187756T patent/ES2982897T3/es active Active
- 2013-11-15 IL IL280144A patent/IL280144B2/en unknown
- 2013-11-15 CN CN202010575187.3A patent/CN111617252A/zh active Pending
- 2013-11-15 DK DK18196690.4T patent/DK3456333T3/da active
- 2013-11-15 MY MYPI2015001459A patent/MY180634A/en unknown
- 2013-11-15 ES ES18196690T patent/ES2789176T3/es active Active
- 2013-11-15 HU HUE19187756A patent/HUE066402T2/hu unknown
- 2013-11-15 EP EP13861008.4A patent/EP2928477B1/en active Active
- 2013-11-15 SI SI201331716T patent/SI3456333T1/sl unknown
- 2013-11-15 MX MX2015007169A patent/MX372753B/es active IP Right Grant
- 2013-11-15 MA MA38193A patent/MA38193B1/fr unknown
- 2013-11-15 HU HUE18196690A patent/HUE049858T2/hu unknown
- 2013-11-15 CA CA3188494A patent/CA3188494A1/en active Pending
- 2013-11-15 SG SG10202103341SA patent/SG10202103341SA/en unknown
- 2013-11-15 HR HRP20240624TT patent/HRP20240624T1/hr unknown
- 2013-11-15 RS RS20200723A patent/RS60401B1/sr unknown
- 2013-11-15 JP JP2015546492A patent/JP6433911B2/ja active Active
- 2013-11-15 IL IL317233A patent/IL317233A/en unknown
- 2013-11-15 SI SI201331556T patent/SI2928477T1/sl unknown
- 2013-11-15 HU HUE13861008A patent/HUE045098T2/hu unknown
- 2013-11-15 UA UAA201505480A patent/UA117116C2/uk unknown
- 2013-11-15 LT LTEP18196690.4T patent/LT3456333T/lt unknown
- 2013-11-15 BR BR112015013260-0A patent/BR112015013260A2/pt not_active Application Discontinuation
- 2013-11-15 EP EP19187756.2A patent/EP3646876B1/en active Active
- 2013-11-15 PL PL13861008T patent/PL2928477T3/pl unknown
- 2013-11-15 ES ES13861008T patent/ES2744790T3/es active Active
- 2013-11-15 PT PT138610084T patent/PT2928477T/pt unknown
- 2013-11-15 SG SG10201802926XA patent/SG10201802926XA/en unknown
- 2013-11-15 LT LTEP13861008.4T patent/LT2928477T/lt unknown
- 2013-11-15 SI SI201332080T patent/SI3646876T1/sl unknown
- 2013-11-15 MY MYPI2020000946A patent/MY200076A/en unknown
- 2013-11-15 AP AP2015008504A patent/AP2015008504A0/xx unknown
- 2013-11-15 PH PH1/2019/501008A patent/PH12019501008A1/en unknown
- 2013-11-15 CN CN201380069553.6A patent/CN104936602B/zh active Active
- 2013-11-15 KR KR1020237005641A patent/KR20230028590A/ko not_active Ceased
- 2013-11-15 CA CA2892907A patent/CA2892907C/en active Active
- 2013-11-15 UA UAA201800703A patent/UA126015C2/uk unknown
- 2013-11-15 PL PL19187756.2T patent/PL3646876T3/pl unknown
- 2013-11-15 WO PCT/US2013/070437 patent/WO2014088785A1/en not_active Ceased
- 2013-11-15 PL PL18196690T patent/PL3456333T3/pl unknown
- 2013-11-15 KR KR1020217026717A patent/KR102662590B1/ko active Active
- 2013-11-15 HR HRP20191784TT patent/HRP20191784T1/hr unknown
- 2013-11-15 EA EA201590878A patent/EA032973B1/ru unknown
- 2013-11-15 ME MEP-2019-273A patent/ME03538B/me unknown
- 2013-11-15 KR KR1020257024576A patent/KR20250114449A/ko active Pending
- 2013-11-15 FI FIEP19187756.2T patent/FI3646876T3/fi active
2015
- 2015-06-04 CL CL2015001530A patent/CL2015001530A1/es unknown
- 2015-06-05 PH PH12015501282A patent/PH12015501282A1/en unknown
- 2015-06-05 TN TNP2015000249A patent/TN2015000249A1/fr unknown
- 2015-06-05 MX MX2022015437A patent/MX2022015437A/es unknown
- 2015-06-05 MX MX2020003276A patent/MX2020003276A/es unknown
- 2015-06-07 IL IL23926615A patent/IL239266B/en active IP Right Grant
- 2015-06-08 ZA ZA2015/04124A patent/ZA201504124B/en unknown
2017
- 2017-08-24 CL CL2017002156A patent/CL2017002156A1/es unknown
- 2017-12-04 JP JP2017232485A patent/JP6998191B2/ja active Active
2018
- 2018-12-20 AU AU2018282364A patent/AU2018282364A1/en not_active Abandoned
2019
- 2019-10-14 CY CY20191101076T patent/CY1122169T1/el unknown
- 2019-12-23 JP JP2019231517A patent/JP2020041001A/ja active Pending
2020
- 2020-06-23 CY CY20201100568T patent/CY1123206T1/el unknown
- 2020-06-24 HR HRP20200993TT patent/HRP20200993T1/hr unknown
- 2020-11-09 AU AU2020267142A patent/AU2020267142C1/en active Active
2021
- 2021-11-12 ZA ZA2021/08991A patent/ZA202108991B/en unknown
2022
- 2022-01-06 JP JP2022000951A patent/JP7288098B2/ja active Active
- 2022-10-12 JP JP2022163881A patent/JP2022179684A/ja not_active Withdrawn
- 2022-11-11 ZA ZA2022/12327A patent/ZA202212327B/en unknown
2024
- 2024-05-13 AU AU2024203138A patent/AU2024203138A1/en active Pending
2025
- 2025-05-05 NL NL301326C patent/NL301326I2/nl unknown
- 2025-05-06 LT LTPA2025517C patent/LTPA2025517I1/lt unknown
- 2025-05-07 HU HUS2500019C patent/HUS2500019I1/hu unknown
- 2025-05-07 FI FIC20250019C patent/FIC20250019I1/fi unknown
- 2025-05-07 FR FR25C1016C patent/FR25C1016I1/fr active Active
- 2025-05-12 JP JP2025080100A patent/JP2025109842A/ja active Pending

Also Published As

Publication number	Publication date
FI3646876T3 (fi)	2024-05-14
JP2016504307A (ja)	2016-02-12
PT3646876T (pt)	2024-05-15
DK2928477T3 (da)	2019-10-07
EP3646876A1 (en)	2020-05-06
HRP20191784T1 (hr)	2019-12-27
MX2022015437A (es)	2023-01-11
SG10202103341SA (en)	2021-05-28
CL2015001530A1 (es)	2016-03-28
MY200076A (en)	2023-12-06
KR20210107906A (ko)	2021-09-01
IL280144B2 (en)	2025-05-01
PT2928477T (pt)	2019-10-25
JP6433911B2 (ja)	2018-12-05
HK1210940A1 (zh)	2016-05-13
HUS2500019I1 (hu)	2025-05-28
KR20230028590A (ko)	2023-02-28
ZA202212327B (en)	2025-03-26
KR20250114449A (ko)	2025-07-29
AP2015008504A0 (en)	2015-06-30
HUE049858T2 (hu)	2020-11-30
JP2022050537A (ja)	2022-03-30
HUE066402T2 (hu)	2024-07-28
HRP20240624T1 (hr)	2024-08-02
AU2024203138A1 (en)	2024-07-25
AU2013356533A1 (en)	2014-06-12
AU2013356533B2 (en)	2018-09-27
PH12015501282B1 (en)	2015-08-24
CN104936602B (zh)	2020-07-17
WO2014088785A1 (en)	2014-06-12
MA45504B1 (fr)	2021-10-29
KR102294819B1 (ko)	2021-09-01
EP3456333A1 (en)	2019-03-20
MA45504A1 (fr)	2020-05-29
ES2789176T3 (es)	2020-10-26
KR20150091130A (ko)	2015-08-07
CY1123206T1 (el)	2021-10-29
EP3456333B8 (en)	2020-05-13
SMT202000328T1 (it)	2020-07-08
PH12015501282A1 (en)	2015-08-24
JP2022179684A (ja)	2022-12-02
NZ748134A (en)	2020-10-30
DK3646876T3 (da)	2024-05-06
MA38193B1 (fr)	2018-12-31
CA3188494A1 (en)	2014-06-12
MX372753B (es)	2020-06-26
MY180634A (en)	2020-12-03
HRP20200993T1 (hr)	2020-11-27
HUE045098T2 (hu)	2019-12-30
FIC20250019I1 (fi)	2025-05-07
NZ708920A (en)	2020-08-28
RS59363B1 (sr)	2019-11-29
CN104936602A (zh)	2015-09-23
LTPA2025517I1 (pl)	2025-05-26
JP7288098B2 (ja)	2023-06-06
BR112015013260A2 (pt)	2018-02-06
SI2928477T1 (sl)	2019-11-29
JP6998191B2 (ja)	2022-02-04
IL280144B1 (en)	2025-01-01
CA2892907A1 (en)	2014-06-12
AU2020267142B2 (en)	2024-05-16
CY1122169T1 (el)	2020-11-25
JP2018035196A (ja)	2018-03-08
UA117116C2 (uk)	2018-06-25
SG11201504383TA (en)	2015-07-30
EP3646876B1 (en)	2024-02-14
MA38193A1 (fr)	2017-12-29
LT3456333T (lt)	2020-06-25
SI3646876T1 (sl)	2024-07-31
AU2020267142A1 (en)	2020-12-03
IL317233A (en)	2025-01-01
LT2928477T (lt)	2019-10-10
AU2018282364A1 (en)	2019-05-23
EP2928477A1 (en)	2015-10-14
EA201590878A1 (ru)	2016-04-29
JP2020041001A (ja)	2020-03-19
MX2020003276A (es)	2020-07-20
RS60401B1 (sr)	2020-07-31
CA2892907C (en)	2023-03-21
JP2025109842A (ja)	2025-07-25
LT3646876T (lt)	2024-05-10
IL239266B (en)	2019-11-28
AU2020267142C1 (en)	2024-08-08
EA032973B1 (ru)	2019-08-30
ZA202108991B (en)	2023-05-31
FR25C1016I1 (fr)	2025-06-20
IL239266A0 (en)	2015-07-30
CN111617252A (zh)	2020-09-04
NL301326I2 (nl)	2025-07-31
SMT201900567T1 (it)	2019-11-13
PT3456333T (pt)	2020-06-01
MX2015007169A (es)	2016-03-31
CL2017002156A1 (es)	2018-05-04
ME03538B (me)	2020-07-20
KR102662590B1 (ko)	2024-05-03
ES2982897T3 (es)	2024-10-18
PL3646876T3 (pl)	2024-07-22
WO2014088785A8 (en)	2015-07-16
IL280144A (en)	2021-03-01
EP3456333B1 (en)	2020-04-01
PL2928477T3 (pl)	2020-03-31
ES2744790T3 (es)	2020-02-26
SI3456333T1 (sl)	2020-10-30
PH12019501008A1 (en)	2022-11-14
UA126015C2 (uk)	2022-08-03
EP2928477B1 (en)	2019-07-24
UA128370C2 (uk)	2024-06-26
TN2015000249A1 (en)	2016-10-03
DK3456333T3 (da)	2020-05-18
ZA201504124B (en)	2017-05-31
EP2928477A4 (en)	2016-09-21
HK1212226A1 (en)	2016-06-10
SG10201802926XA (en)	2018-05-30

Publication	Publication Date	Title
HUS2500019I1 (hu)	2025-05-28	A telomerázgátló imetelstat alkalmazása mielodiszpláziás szindróma kezelésére
IL283943A (en)	2021-07-29	Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
IL285843A (en)	2021-09-30	Ibrutinib for use in the treatment of chronic graft versus host disease
IL243976A0 (en)	2016-04-21	kdm1a inhibitors for disease treatment
SMT201700003B (it)	2017-03-08	Didropiridoni come inibitori del fattore xia
DK2919796T3 (da)	2021-05-31	Brug af akkermansia til behandling af stofskiftesygdomme
IL240519A0 (en)	2015-10-29	Amide compounds for the treatment of AIDS
LT2984166T (lt)	2020-08-10	Kompozicijos, skirtos mpsi gydymui
PL3542798T3 (pl)	2025-09-08	Aceklidyna do zastosowania w leczeniu starczowzroczności
LT2885010T (lt)	2020-04-27	Tautopatijos gydymo būdai
SI3513806T1 (sl)	2023-04-28	Sestava imunogena
EP2863748A4 (en)	2015-12-09	1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
HUE042763T2 (hu)	2019-07-29	Módosított szerpinek vérzési rendellenességek kezelésére
LT3495495T (lt)	2021-02-25	Diagnostiniai žymenys ląstelių proliferacijos sutrikimų gydymui telomerazės inhibitoriais
PL2900230T3 (pl)	2019-02-28	Związki do leczenia otyłości i sposoby ich zastosowania
LT2812013T (lt)	2019-07-10	Kompozicija, skirta džs gydymui
PL2846791T3 (pl)	2017-07-31	HPN-100 do zastosowania do leczenia zaburzeń retencji azotu
ZA202207530B (en)	2023-10-25	Use of phenoxypropylamine compounds to treat depression
DK2988750T4 (da)	2025-08-18	Anvendelse af landiololhydrochlorid til langtidsbehandling af takyarytmier
ITRM20120473A1 (it)	2014-04-05	Use of glycerophosphoinositols for the treatment of septic shock
DK2976101T3 (da)	2020-11-23	Behandlingsfremgangsmåde
DK3041506T3 (da)	2023-02-27	Behandlingsfremgangsmåde
TH1501001181A (th)	2016-08-03	องค์ประกอบสำหรับรักษาโรคสะเก็ดเงิน
FI20126161L (fi)	2014-05-08	Seinän pintakäsittely
TH1401007179A (th)	2016-07-06	องค์ประกอบและการใช้ของมันเพื่อป้องกันและรักษาตับอักเสบบี